Core Laboratories INC /DE/

Core Laboratories Inc. announced second quarter 2026 financial results, showing sequential revenue improvement and a significant sequential increase in operating income, despite ongoing geopolitical conflicts impacting operations.

Core Laboratories shareholders approved the election of directors, the appointment of KPMG as auditor, and executive compensation at the 2026 Annual Meeting.

Core Laboratories Inc. reported first quarter 2026 financial results showing a sequential revenue decline and a significant drop in operating income, primarily attributed to geopolitical events in the Middle East and other global disruptions.

Core Laboratories Inc. revises its first quarter 2026 earnings guidance downward due to regional instability and operational disruptions in the Middle East.

Core Laboratories Inc. filed an amended report to correct a $4.2 million understatement of income tax expense for the quarter and year ended December 31, 2025, impacting net income and EPS.

Core Laboratories Inc. has amended its bylaws to reduce the shareholder voting threshold for significant corporate actions, including mergers and change in control transactions, from a 66-2/3% supermajority to a 50% plus one simple majority.

Core Laboratories Inc. reported a significant decrease in net income for Q2 2026 compared to the prior year, impacted by geopolitical conflicts and supply chain disruptions.

Core Laboratories Inc. announced a 21% year-over-year increase in net income for Q3 2025, driven by operational efficiencies and international service demand, despite flat total revenue.

Core Laboratories Inc. reported a significant sequential rebound in net income and revenue for the second quarter of 2025, despite flat year-over-year revenue and ongoing geopolitical and trade uncertainties.

Core Laboratories' Q1 2025 results reflect a decrease in revenue and operating income, impacted by geopolitical conflicts and sanctions, though partially offset by growth in well completion diagnostic services.

Core Laboratories Inc. announced its Q3 2024 results, showing a 7% increase in total revenue and a 27% increase in net income attributable to Core Laboratories Inc. compared to the same period last year.

Core Laboratories Inc. reports a mixed second quarter with a slight revenue increase but a significant decrease in net income compared to the previous year.

Core Laboratories Inc. reported a slight revenue increase in 2025, driven by service growth, but saw declines in net income and product sales amidst geopolitical conflicts and a challenging international exploration environment.

Core Laboratories' 2024 10-K filing reveals a year of international growth offset by challenges in the U.S. onshore market, with a focus on reservoir description and production enhancement services.

Core Laboratories Inc.'s 10-K filing provides a comprehensive overview of the company's business, financial performance, and potential risks, including details on its share structure and international operations.

Lawrence Bruno, Chairman and CEO and a Director of Core Laboratories Inc. /DE/, purchased 5,000 shares of common stock on July 31, 2026 for $10.78 per share.

Sow Hang Teo, CAO & Treasurer of Core Laboratories Inc. /DE/, reported multiple transactions in common stock on August 1, 2026.

Mark Damian Tattoli, SVP, Gen Counsel & Secretary of Core Laboratories Inc. /DE/, reported multiple transactions in common stock on August 1, 2026.

Mark Tattoli, SVP, Gen Counsel & Secretary of Core Laboratories Inc., reported transactions involving company stock on May 1, 2026.

Katherine Murray, a Director at Core Laboratories Inc., has acquired 8,069 shares of common stock.

Director Curt Anastasio of Core Laboratories Inc. reported transactions involving restricted shares, with a portion vesting and a new grant of restricted shares.

Core Laboratories Inc. announces its 2026 annual meeting of shareholders to address director re-election, auditor ratification, and advisory vote on executive compensation, alongside disclosures on financial performance and geopolitical risks.

Core Laboratories Inc. will hold its annual shareholder meeting on May 21, 2025, to elect directors, ratify the appointment of KPMG LLP as independent accountants, and approve executive compensation.

Core Laboratories Inc. sets date for its 2025 annual shareholder meeting and outlines key proposals, including director elections, auditor ratification, and executive compensation approval.

Core Laboratories Inc. will hold its annual shareholder meeting on May 8, 2024, to vote on director elections, auditor ratification, executive compensation, and an amendment to the long-term incentive plan.

Core Laboratories is asking shareholders to approve an amendment and restatement of its 2020 Long-Term Incentive Plan to increase the number of authorized shares and extend the plan's term.

Disciplined Growth Investors, Inc. has filed an amendment to its Schedule 13G, reporting a 10.7% beneficial ownership stake in Core Laboratories Inc.

The Vanguard Group reports zero beneficial ownership in Core Laboratories Inc. common stock following an internal realignment.

EARNEST Partners LLC has filed an amended Schedule 13G, reporting a 6.9% beneficial ownership stake in Core Laboratories Inc. /DE/ common stock.

Disciplined Growth Investors Inc. reported an increased beneficial ownership of 12.8% in Core Laboratories Inc., holding 5,969,860 common shares.

Ariel Investments, LLC has filed an amended Schedule 13G, reporting a 29.4% beneficial ownership stake in Core Laboratories Inc.

The Vanguard Group has reported an increased beneficial ownership of 6.49% in Core Laboratories Inc., holding over 3 million shares.